Attached files
| file | filename |
|---|---|
| 10-K - 10-K - Wave Life Sciences Ltd. | wve-10k_20171231.htm |
| EX-32 - EX-32 - Wave Life Sciences Ltd. | wve-ex32_6.htm |
| EX-31.2 - EX-31.2 - Wave Life Sciences Ltd. | wve-ex312_7.htm |
| EX-31.1 - EX-31.1 - Wave Life Sciences Ltd. | wve-ex311_8.htm |
| EX-21.1 - EX-21.1 - Wave Life Sciences Ltd. | wve-ex211_10.htm |
| EX-10.9.2 - EX-10.9.2 - Wave Life Sciences Ltd. | wve-ex1092_563.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Wave Life Sciences Ltd.:
We consent to the incorporation by reference in the registration statements (No. 333-208598 and No. 333-221480) on Form S-8 and (No. 333-215428) on Form S-3, as amended, of Wave Life Sciences Ltd., of our report dated March 12, 2018, with respect to the consolidated balance sheets of Wave Life Sciences Ltd. as of December 31, 2017 and 2016 and the related consolidated statements of operations, comprehensive loss, Series A preferred shares and shareholders’ equity and cash flows for each of the years in the three-year period ended December 31, 2017, and the related notes (collectively, the “consolidated financial statements”), which report appears in the December 31, 2017 annual report on Form 10-K of Wave Life Sciences Ltd.
/s/ KPMG LLP
Cambridge, Massachusetts
March 12, 2018